SYSMALVAC

Identifying correlates of protection to accelerate vaccine trials: systems evaluation of two models of experimentally-induced immunity to malaria

Coordinatore	FUNDACIO CENTRE DE RECERCA EN SALUT INTERNATIONAL DE BARCELONA    more  Organization address address: CALLE VILLARROEL 170 city: Barcelona postcode: 8036 contact info Titolo: Dr. Nome: Carlota Cognome: Dobaño Email: send email Telefono: 34932279892
Nazionalità Coordinatore	Spain [ES]
Totale costo	3˙635˙594 €
EC contributo	2˙803˙651 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-01-01   -   2014-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACIO CENTRE DE RECERCA EN SALUT INTERNATIONAL DE BARCELONA  Organization address address: CALLE VILLARROEL 170 city: Barcelona postcode: 8036 contact info Titolo: Dr. Nome: Carlota Cognome: Dobaño Email: send email Telefono: 34932279892	ES (Barcelona)	coordinator	711˙450.10
2	PROGENIKA BIOPHARMA SA  Organization address address: "Parque Tecnologico de Zamudio, Edificio 801 -A-, Planta 2" city: DERIO - VIZCAYA postcode: 48160 contact info Titolo: Mr. Nome: Gorka Cognome: Ramirez Email: send email Telefono: 34944064525 Fax: 34944064526	ES (DERIO - VIZCAYA)	participant	616˙980.00
3	EBERHARD KARLS UNIVERSITAET TUEBINGEN  Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 contact info Titolo: Dr. Nome: Benjamin Cognome: Mordmueller Email: send email Telefono: +49 7071 2982187	DE (TUEBINGEN)	participant	324˙042.00
4	SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT  Organization address address: SOCINSTRASSE 57 city: Basel postcode: CH-4002 contact info Titolo: Mr. Nome: Daniel Cognome: Thommen Email: send email Telefono: 41612848316 Fax: 41612848118	CH (Basel)	participant	314˙870.40
5	ANAXOMICS BIOTECH, S.L.  Organization address address: CALLE BALMES (PISO 4 - PTA 2A) 89 city: Barcelona postcode: 8008 contact info Titolo: Ms. Nome: Vesna Cognome: Radovanovic Email: send email Telefono: +34 934 516 717	ES (Barcelona)	participant	294˙534.00
6	STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER  Organization address address: LANGE KLEIWEG 161 city: RIJSWIJK ZH postcode: 2288 GJ contact info Titolo: Dr. Nome: Clemens Cognome: Kocken Email: send email Telefono: 31152842775	NL (RIJSWIJK ZH)	participant	276˙975.00
7	STICHTING KATHOLIEKE UNIVERSITEIT  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Dr. Nome: Annemieke Cognome: Jansens Email: send email Telefono: 31243610577 Fax: 31243540216	NL (NIJMEGEN)	participant	264˙800.40

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Vaccine development is an empirical process (trial and error) and involves a long, expensive clinical development pipeline to license an efficacious vaccine candidate. Better tools for vaccine evaluation are needed to adapt to a rising number of candidate vaccines entering clinical trials for many diseases. Surrogate biomarkers of immunity offer the possibility of expediting the clinical development by eliminating non-viable candidates earlier in the pipeline, shortening vaccine trial timeframes by giving a proxy measurement for efficacy and by guiding future vaccine design. In the case of malaria and other complex diseases, a surrogate biomarker of immunity has been difficult to achieve with classical immunological assays. We propose using a systems biology analytical approach in two efficacious malaria vaccination models to identify combinatorial biomarkers of protection. First, newly generated cellular transcriptome profiles and previously generated immunological read-outs common to both trials will be integrated into a database for this analysis. An already developed artificial intelligence-based analytical tool that generates biological network maps, transforms experimental data to the map and discriminates transcriptional gene signatures to physiological states (protection or susceptibility) will be applied in both vaccination models. The aim is to determine malaria signatures of protection that will then be refined and validated in an experimentally induced immunity non-human primate model. The optimized model will be further validated on additional samples from the two protective human trials. The identified biomarkers of protection will be used to produce a customised Immunome Chip, which together with traditional immunological read-outs will be used to evaluate vaccine efficacy, shortening times and costs of clinical trials. This strategy may also prove useful for other diseases and support the systems medicine approach.'